You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Cancer is America's second leading cause of death. Many approved cancer drugs, such as bortezomib (Velcade), are cytotoxic agents that kill normal cells as well as tumor cells. Therapeutic benefit depends on tumor cellsbeing more sensitive than normal cells, thereby allowing clinical responses to be achieved at relatively safe drug doses; however, damage t ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Cancer is the second leading cause of death after heart disease in the US Chemotherapy is a mainstay of treatment after surgical removal of tumors but the balance of clinical benefit versus disabling or life threatening side effects is often uncertain Genotyping of cancers to identify mutated oncogenes has enabled an era of targeted therapy Drugs targeting ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. AFARI: A Stylized Adaptive Mobility and Fitness Device for Outdoor Movement

    SBC: R M BEAUMONT CORP            Topic: NIA

    DESCRIPTION provided by applicant Osteoarthritis OA diagnosed in over of the US population is the primary cause of musculoskeletal lower extremity disability Although there is no cure exercise remains the core treatment to manage OA regardless of age comorbidity pain severity or disability Yet many people with this condition do not engage in regular fitness and thus may resort t ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. AFM based nanoscale IR Spectroscopy (AFM-IR) as a characterization platform for P

    SBC: Anasys Instruments Corp.            Topic: 300

    DESCRIPTION provided by applicant Anasys Instruments and Prof Lynne Taylor of Purdue propose to develop nanoscale chemical characterization capabilities for drug formulation research This project will build on successful Phase I research demonstrating feasibility of atomic force microscope based infrared spectroscopy AFM IR in pharmaceutical applications This Phase II research will advance ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. A Genes-to-Molecules Platform for Expanding Natural Product Diversity

    SBC: Lassogen, Inc.            Topic: NCCIH

    Project Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. A Genetic Test for Drug-Induced Dyskinesia Risk

    SBC: KOVOGEN            Topic: N/A

    DESCRIPTION (provided by applicant): The objective of this project is to develop a genetic test, involving the protein, RGS9, to identify patients that are at risk for developing tardive dyskinesia (TD) or L-DOPA induced dyskinesia (LID). Antipsychotic drugs have revolutionized the treatment of schizophrenia and psychotic disorders but a debilitating side-effect of "typical" antipsychotics is TD, ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1

    SBC: VELUM INC            Topic: NIA

    There is a world wide twin epidemic of obesity and TypeDiabetesT Dwith an urgent need to find effective new drug treatments for inducing weight lossStable derivatives of the endogenous glucoregulatory hormoneglucagon like peptideGLPare in clinical use for the treatment of T D but are of equally great interest as an emerging treatment of obesity and of age related neurodegenerative conditions inclu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1

    SBC: VELUM INC            Topic: NIA

    Project Summary There is a world-wide “twin epidemic” of obesity and Type 2 Diabetes (T2D), with an urgent need to find effective new drug treatments for inducing weight loss. Stable derivatives of the endogenous glucoregulatory hormone, glucagon-like peptide-1 (GLP1) are in clinical use for the treatment of T2D but are also of great interest as an emerging treatment of obesity. Another closel ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. A high-throughput kit for detection of RNA modifications

    SBC: MAVERIX BIOMICS, INC.            Topic: NIDA

    DESCRIPTION provided by applicant The broad objective of this project is to develop an integrated wet lab dry lab kit for high throughput detection of RNA modifications The final product will provide all required molecular biology reagents a set of simple and robust experimental manipulations for facile analysis of modifications and researcher friendly analytic cloud based software requi ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. A Home Exercise Program (DVD) for Women with Infants and Young Children

    SBC: KLEIN BUENDEL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Becoming a mother is a significant transition in a woman's life. It is associated with considerable social, personal, career/job, and financial changes. Such transitions can precipitate major changes in health behaviors , like physical activity (PA). Up to one-year postpartum 57 percent of women are rarely or never exercising. With subsequent pregnancies women ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government